COVID-19: Weekly Life Sciences Digest – International Collaboration and Adjusted Exports/Import Rules
With COVID-19 heralding unprecedented changes in the sector, our life sciences products experts provide a weekly summary of key international developments to keep you up to date.
Cooley’s international products law team are pleased to announce the fourth event in its webinar series. This webinar will look at the European Union’s approach to Artificial Intelligence including the impact of the European Commission’s White Paper on Artificial Intelligence. The team will be joined by members of Cooley’s Technology […]
UK-specific guidance for the application and management of clinical trials in the context of COVID-19
The UK’s MHRA has stated it will be particularly flexible and pragmatic in authorising clinical trials connected to COVID-19, referring to its previous track record of having acted swiftly in past public health crises
Cooley’s international products law team is pleased to announce the third event in its webcast series looking at the latest consumer rights issues product manufacturers, suppliers and other stakeholders are facing in the rapidly changing global environment. This time we will be joined by Wendy Hederman, a partner at leading Irish law […]
UK food safety watchdog issues warning to CBD businesses that their products could be ‘taken off the shelves’ if the industry fails to submit valid novel food authorisation applications by 31 March 2021.
In such unprecedented times, international product regulators are finding themselves under increasing pressure and seem to be reacting with a previously unseen level of agility and flexibility. We look at what is happening, globally. Is it business as usual? What are we seeing them focus on? And what does this mean for the future of products regulations?
We all hope that the predictions about the spread and seriousness of COVID-19 (coronavirus) prove to be unfounded. Whatever course the development of the virus takes, many of the measures that have been taken or are under consideration by governments, businesses and other organisations are already having or will have a significant effect on commercial relationships and commercial life generally.